Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 4, 2008 - Issue 2
Submit an article Journal homepage
201
Views
26
CrossRef citations to date
0
Altmetric
Expert Opinion

Update on the use of pramipexole in the treatment of Parkinson’s disease

Radu ConstantinescuDepartment of Neurology, Sahlgrenska University Hospital413 45 Göteborg, SwedenCorrespondence[email protected]
Pages 337-352 | Published online: 11 Apr 2008

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Silvia Rota, Iro Boura, Lucia Batzu, Nataliya Titova, Peter Jenner, Cristian Falup-Pecurariu & K Ray Chaudhuri. (2020) ‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine. Expert Review of Neurotherapeutics 20:9, pages 953-965.
Read now
Abdul Qayyum Rana, Uzma S Ahmed, Zishan M Chaudry & Sai Vasan. (2015) Parkinson’s disease: a review of non-motor symptoms. Expert Review of Neurotherapeutics 15:5, pages 549-562.
Read now
Fatai Kunle Salawu. (2012) Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole. Patient Preference and Adherence 6, pages 49-54.
Read now

Articles from other publishers (23)

Robert A. Hauser, Nir Giladi, Werner Poewe, Jonathan Brotchie, Hadas Friedman, Sheila Oren & Pninit Litman. (2022) P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease. Advances in Therapy 39:5, pages 1881-1894.
Crossref
Ehsan Ziaei, Parisa Emami Ardestani & Ahmad Chitsaz. (2022) Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease: A randomized parallel-group trial. Journal of Research in Medical Sciences 27:1, pages 55.
Crossref
Trang N. N. Vo, Karen Frei & Daniel D. Truong. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 2993 3013 .
Sarah Marmol, Matthew Feldman, Carlos Singer & Jason Margolesky. (2021) Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?. CNS Drugs 35:11, pages 1141-1152.
Crossref
Laura Andreoli, Morteza Abbaszadeh, Xiao Cao & Maria Angela Cenci. (2021) Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism. Neurobiology of Disease 157, pages 105429.
Crossref
E. Maruthi Prasad & Shih-Ya Hung. (2021) Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update. Pharmaceuticals 14:8, pages 717.
Crossref
Violina Kakoty, Sarathlal K C, Sunil Kumar Dubey, Chih Hao Yang, Prashant Kesharwani & Rajeev Taliyan. (2021) The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy. Neuroscience Letters 753, pages 135865.
Crossref
Paloma Parra‐Díaz, Juan Luis Chico‐García, Álvaro Beltrán‐Corbellini, Fernando Rodríguez‐Jorge, Clara Lastras Fernández‐Escandón, Araceli Alonso‐Cánovas & Juan Carlos Martínez‐Castrillo. (2020) Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review. Movement Disorders Clinical Practice 8:1, pages 25-32.
Crossref
Wen Kang Chou, Mathini Vaikunthan, Hendrik V. Schröder, A. James Link, Hahn Kim & Mark P. Brynildsen. (2020) Synergy Screening Identifies a Compound That Selectively Enhances the Antibacterial Activity of Nitric Oxide. Frontiers in Bioengineering and Biotechnology 8.
Crossref
Dan Luo, Maarten Reith & Aloke K. Dutta. 2020. Diagnosis and Management in Parkinson's Disease. Diagnosis and Management in Parkinson's Disease 445 460 .
Sunpreet Kaur, Shamsher Singh, Gagandeep Jaiswal, Sandeep Kumar, Wafa Hourani, Bapi Gorain & Puneet Kumar. 2020. Frontiers in Pharmacology of Neurotransmitters. Frontiers in Pharmacology of Neurotransmitters 143 182 .
Trang N. N. Vo, Karen Frei & Daniel D. Truong. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 21 .
Graham K. Murray, Franziska Knolle, Karen D. Ersche, Kevin J. Craig, Sanja Abbott, Shaila S. Shabbir, Naomi A. Fineberg, John Suckling, Barbara J. Sahakian, Edward T. Bullmore & Trevor W. Robbins. (2019) Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder. Psychopharmacology 236:8, pages 2325-2336.
Crossref
Pallavi Rane, Deepaneeta Sarmah, Shashikala Bhute, Harpreet Kaur, Avirag Goswami, Kiran Kalia, Anupom Borah, Kunjan R. Dave, Nutan Sharma & Pallab Bhattacharya. (2018) Novel Targets for Parkinson’s Disease: Addressing Different Therapeutic Paradigms and Conundrums. ACS Chemical Neuroscience 10:1, pages 44-57.
Crossref
Masahiro Nomoto, Hirotaka Iwaki, Hiroyuki Kondo & Masaya Sakurai. (2017) Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials. Journal of Neurology 265:2, pages 253-265.
Crossref
Adeline Cardon-Dunbar, Tom Robertson, Michael S. Roberts & Geoffrey K. Isbister. (2017) Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus. Journal of Medical Toxicology 13:4, pages 343-346.
Crossref
Ahmed Naguy. (2017) Successful Treatment of a Child with Difficult-to-Treat Chronic Selective Mutism Using Pramipexole. Journal of Child and Adolescent Psychopharmacology 27:4, pages 393-394.
Crossref
Jennifer L. Walters & Merle G. Paule. (2017) Review of preclinical studies on pediatric general anesthesia-induced developmental neurotoxicity. Neurotoxicology and Teratology 60, pages 2-23.
Crossref
Sumit Sarkar, James Raymick & Syed Imam. (2016) Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives. International Journal of Molecular Sciences 17:6, pages 904.
Crossref
Ashish Kumar Kakkar & Neha Dahiya. (2015) Management of Parkinson׳s disease: Current and future pharmacotherapy. European Journal of Pharmacology 750, pages 74-81.
Crossref
James E. Frampton. (2014) Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease. Drugs 74:18, pages 2175-2190.
Crossref
Mine Silindir & A. Yekta Ozer. (2014) The benefits of pramipexole selection in the treatment of Parkinson’s disease. Neurological Sciences 35:10, pages 1505-1511.
Crossref
Michael Schachter. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions 281 294 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.